Purple Biotech has entered a Phase II trial with its small molecule drug, NT219, focusing on patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).

Patients with lung cancer, breast cancer, prostate cancer, cancer with an unknown primary site, or renal cancer are at high risk for the development of SCC by metastatic tumor. Spinal cord ...

Five-year data from the KEYNOTE-048 trial support the use of pembrolizumab and pembrolizumab-chemotherapy as standards of care, researchers wrote.

The reported risk for metastasis in squamous cell carcinomas (SCCs) ranges from 0.5% to 16%, a wide spread that can probably be explained by differences in patient populations. Identifying the ...

A recent study published in Engineering has shed new light on the mechanisms underlying the metastasis of head and neck squamous cell carcinoma (HNSCC).The research identified enolase 2 (ENO2), a ...

Nivolumab is already an FDA approved treatment for recurrent metastatic squamous cell carcinoma of the head and neck. The authors of the JAMA publication stated: “Taken together the DEPEND ...

Anti-PD1 immunotherapy improves outcomes for patients with metastatic cutaneous squamous cell carcinoma (cSCC ... and cSCC of the head and neck are more likely to die of their cancer than ...

Importantly, these photoprotected lesions demonstrate higher rates of metastasis. Hispanic men have noticeably high rates of penile SCC (age-adjusted ... of the head and neck are more likely ...

Compared to the broader NCCN risk stratification, when DecisionDx-SCC was combined with BWH staging, Class 1 (low risk) test results showed a nearly two-fold decrease in metastatic risk and Class ...

Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated ...

HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCCUpdated data from ongoing Phase 1/1b trial in 1L ...